Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Levi Garraway
Country of residence : Unknown
Linked companies : Roche Holding AG

Summary 
Founder of Foundation Medicine, Inc. and Tango Therapeutics Sub, Inc., Levi A. Garraway currently occupies the position of Chief Medical Officer for Roche Holding AG and Director, Chief Medical Officer & Executive VP at Genentech, Inc. (a subsidiary of Roche Holding AG).

In the past Dr. Garraway occupied the position of Senior VP-Global Development & Medical Affairs at Eli Lilly & Co.




Current positions of Levi Garraway 
Levi Garraway : Personal Network 
Most Read News 
09/28Buffett's Berkshire Hathaway buys 5.99 million more Occidental shares
RE
09/26Unilever's soap opera: M&A, Nelson Peltz, CEO to retire
RE
09/20JPMorgan CEO Dimon to warn Congress of economic 'storm clouds' -testimony
RE
09/26Twitter to interview Elon Musk, known for combative testimony
RE
09/21Trump ally Barrack's trial on foreign agent charges moves to opening statements
RE
09/28Elon Musk seeks to narrow SEC consent decree, end pre-approval of tweets
RE
09/29The long, winding road to Volkswagen's Porsche IPO
RE
09/20Palihapitiya to wind down two blank-check firms as choppy markets deter valuations
RE
09/21Bloomberg to spend $85 million against U.S. plastic, petrochem buildout
RE
09/21Samsung Elec's Lee says SoftBank's Son expected to visit Seoul -media
RE
More news


© 2022 People and Ownership :   
Levi Garraway : Connections 


Latest news about Levi Garraway 
09/12Transcript : Roche Holding AG - Special Call
CI
06/08Roche's Tecentriq Gets EU Approval as Adjuvant Treatment for Cancer Type
DJ
05/11Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
RE
05/11Blow to Roche's cancer immunotherapy prospects as 2nd trial fails
RE
03/30New cancer immunotherapy fails in first Roche trial
RE
2021EU Approves Roche's Actemra/RoActemra Against Severe Covid-19
DJ
2021Press Release : Ronapreve approved by European Commission to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease
DJ
More news